Pharmacological properties of 5-hydroxytryptamine4 receptor antagonists on constitutively active wild-type and mutated receptors

Molecular Pharmacology

Volumn 58, Issue 1, 2000, Pages 136-144

  Claeysen, Sylvie ^a   Sebben, Michèle ^a   Bécamel, Carine ^a   Eglen, Richard M ^b   Clark, Robin D ^b   Bockaert, Joël ^a   Dumuis, Aline ^a  

^a CNRS   (France)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 1 BENZIMIDAZOLECARBOXYLIC ACID 6 METHOXY 3ALPHA TROPANYL ESTER; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (1 PIPERIDINYL)ETHYL ESTER; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (3,5 DIMETHYLPIPERIDINO)ETHYL ESTER; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (DIETHYLAMINO)ETHYL ESTER; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 3 PIPERIDINOPROPYL ESTER; 5 FLUORO 2 METHOXY 1H INDOLE 3 CARBOXYLIC ACID 1 [2 (METHYLSULFONAMIDO)ETHYL] 4 PIPERIDINYLMETHYL ESTER; 8 AMINO 7 CHLORO 1,4 BENZODIOXAN 5 CARBOXYLIC ACID 1 BUTYL 4 PIPERIDINYLMETHYL ESTER; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; N [2 [4 (1 ADAMANTANECARBOXAMIDO) 1 PIPERIDINYL]ETHYL] 1 ISOPROPYL 1H INDAZOLE 3 CARBOXAMIDE; PIBOSEROD; RADIOLIGAND; RS 100235; RS 100303; RS 100350; RS 39604; RS 47109; RS 47431; RS 54580; RS 57261; RS 67532; RS 79842; SEROTONIN; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DENSITY; SUPERIOR COLLICULUS;

EID: 0033949566     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.58.1.136     Document Type: Article

References (37)

1. 4 receptor. Eur J Pharmacol 304:231-235.
2. Ambrosio C, Molinari P, Cotecchia S and Costa T (2000) Catechol-binding serines of beta(2)-adrenergic receptors control the equilibrium between active and inactive receptor states. Mol Pharmacol 57:198-210.
3. 4 receptors in neurone. Eur J Pharmacol 298:165-174.
4. Barlow HB (1964) Dark-adaptation: A new hypothesis. Vision Res 4:47-58.
5. Blondel O, Gastineau M, Langlois M and Fischmeister R (1998) The 5-HT4 receptor antagonist ML 10375 inhibits the constitutive activity of human 5-HT4c receptor. Br J Pharmacol 125:595-597.
6. 4 receptors. Potential therapeutic implications in neurology and psychiatry. Cent Nerv Syst Drugs 1:6-15.
7. 4 Receptors: An update, in Handbook of Experimental Pharmacology: Serotoninergic Neurons and 5-HT Receptors in the CNS (Baumgarten HG and Göthert M eds) pp 439-465, Springer Verlag, Berlin.
8. Bond RA, Leff P, Johnson TD, Milano CR, Rockman HA, McMinn TR, Apparsundaran S, Hyek MF, Kenakin TP, Allen LF and Lefkowitz RJ (1995) Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of β2-adrenoceptor. Nature (Lond) 374:272-276.
9. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 72:248-254.
10. Braun S and Levitsky A (1979) Adenosine receptor permanently coupled to turkey erythrocyte adenylate cyclase. Biochemistry 18:2134-2138.
11. Chen G, Way J, Armour S, Watson C, Queen K, Jayawickreme CK, Chen WJ and Kenakin T (2000) Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol 57:125-134
12. Chidiac P, Hebert TE, Valiquette M, Dennis M and Bouvier M (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 46:490-499.
13. Claeysen S, Faye P, Sebben M, Lemaire S, Bockaert J and Dumuis A (1997) Cloning and expression of human 5-HT4S receptors. Effect of receptor density on their coupling to adenylyl cyclase. Neuroreport 8:3189-3196.
14. Claeysen S, Sebben M, Becamel C, Bockaert J and Dumuis A (1999) Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: Role of the C-terminal intracellular domain. Mol Pharmacol 56:910-920.
15. 4L receptor. FEBS Lett 398:19-25.
16. 4 Receptors in the Brain and Periphery (Eglen RM ed) pp 1-48, Springer Verlag, Berlin.
17. Colquhoun D (1973) The relation between classical and cooperative models for drug action, in Drug Receptors (Rang HP ed) pp 149-174, University Park Press, Baltimore.
18. Costa T, Ogino Y, Munson PJ, Onaran HO and Rodbard D (1992) Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors; thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 41:549-560.
19. Dumuis A, Bouhelal R, Sebben M, Cory R and Bockaert J (1988) A non classical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol 34:880-887.
20. 4 receptors: Physiology, pharmacology and therapeutic potential. Exp Opin Invest Drugs 5:373-388.
21. Gaster L and King FD (1997) Serotonin 5-HT3 and 5-HT4 receptor antagonists. Med Res Rev 17:163-214.
22. Karlin A (1967) On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. J Theor Biol 16:306-320.
23. Kenakin T (1996) The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 48:413-463.
24. Kenakin TP and Morgan PH (1989) Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists. Mol Pharmacol 1:445-451.
25. 1B-adrenergic receptor by all amino acid substitutions at a single site. J Biol Chem 267:1430-1433.
26. Langlois M, Zhang L, Yang D, Brémont B, Shen S, Manara L and Croci T (1994) Design of a potent 5-HT4 receptor agonist with nanomolar affinity. Bioorg Med Chem Lett 4:1433-1436.
27. Leff P (1988) Analysis of the agonist action using the operational model. Trends Pharmacol Sci 9:935-937.
28. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
29. Lefkowitz RJ, Cotecchia S, Samana P and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-304.
30. Monod J, Wyman J and Changeux J-P (1965) On the nature of allosteric transitions: A plausible model. J Mol Biol 12:88-118.
31. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4635.
32. Seifert R, Wenzel-Seifert K and Kobilka BK (1999) GPCR-Galpha fusion proteins: Molecular analysis of receptor-G-protein coupling. Trends Pharmacol Sci 20:383-389.
33. Surya A, Foster KW and Know BE (1995) Transducin activation by bovine opsin apoprotein. J Biol Chem 270:5024-5031.
34. Thron CD (1970) Graphical and weighted regression anlyses for the determination of agonist dissociation constants. J Pharmacol Exp Ther 175:541-553.
35. Waldhoer M, Wise A, Milligan G, Freissmuth M and Nanoff C (1999) Kinetics of ternary complex formation with fusion proteins composed of the A(1)-adenosine receptor and G protein alpha-subunits. J Biol Chem 274:30571-30579.
36. Yang D, Soulier JL, Sicsic S, Mathe-Allainmat M, Bremont B, Croci T, Cardamone R, Aureggi G and Langlois M (1997) New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors. J Med Chem 40:608-621.
37. Zhong H, Guerrero SW, Esbenshade TA and Minneman KP (1996) Inducible expression of B1- and B2-adrenergic receptors in rat C6 glioma cells: Functional interactions between closely related subtypes. Mol Pharmacol 50:175-184.